Result card

  • CUR9: What are the differences in the management for the different stages of the Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI)?
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment
A0017
English
Guidance

What are the differences in the management for the different stages of the Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI)?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

There are no established treatments for MCI.

In contrast to MCI, there are several pharmacological possibilities for the treatment of AD. Currently available drug treatments for AD are considered symptomatic. It is recommended that patients with AD and mild to moderate dementia are initially treated with one of the cholinesterase inhibitors (ChEIs), i.e. donepezil, galantamine, or rivastigmine {30} {38} {89}. These drugs have been shown as having efficacy on cognitive function, global outcome, and ADL functions {38}. ChEIs can be used also in the severe form of AD either alone or in combination with the glutamate antagonist memantine {38}. Memantine can also be used alone in patients with severe AD and in patients who have contraindications or who are intolerant to ChEIs {38}. See also {CUR12}.

Important
Completely
Migliore A et al. Result Card CUR9 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 June 2022]. Available from: http://corehta.info/ViewCover.aspx?id=267

References

  • {30}  Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, et al. 4th canadian consensus conference on the diagnosis and treatment of dementia. Can J Neurol Sci. 2012 Nov;39(6 Suppl 5):S1-8.
  • {38}  Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of alzheimer's disease. Eur J Neurol. 2010 Oct;17(10):1236-48.
  • {89}  NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111). 2011.